StockData
ANI Pharmaceuticals Inc logo

ANI Pharmaceuticals Inc (ANIP) stock

ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$69.99−0.90 (-1.27%)

Close on Nov 17, 2026Market cap $1.61BP/E 14.9Yield –

ANI Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

ANI Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was $189.47M, up 36.2% year over year. For fiscal 2025 it was $185.23M, up 189.3% from the year before. Over ten years it grew 26.8% a year on average. The highest annual figure on record is $185.23M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$185.23M+189.3%
FY2024Dec 31, 2024$64.02M-46.2%
FY2023Dec 31, 2023$118.96M–
FY2022Dec 31, 2022-$31.20M-1039.3%
FY2021Dec 31, 2021$3.32M-78.2%
FY2020Dec 31, 2020$15.27M-66.5%
FY2019Dec 31, 2019$45.63M-32.0%
FY2018Dec 31, 2018$67.07M+70.2%
FY2017Dec 31, 2017$39.42M+43.5%
FY2016Dec 31, 2016$27.47M+59.1%
FY2015Dec 31, 2015$17.26M-21.6%
FY2014Dec 31, 2014$22.03M–
FY2013Dec 31, 2013-$5.48M–
FY2012Dec 31, 2012-$137.00K–
FY2011Dec 31, 2011-$47.87M–
FY2010Dec 31, 2010-$40.10M–
FY2009Dec 31, 2009-$18.43M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$56.67M-25.3%
Q1 FY2026Mar 31, 2026$58.38M+66.8%
Q4 FY2025Dec 31, 2025$30.37M+91.5%
Q3 FY2025Sep 30, 2025$44.06M+253.2%
Q2 FY2025Jun 30, 2025$75.81M+335.4%
Q1 FY2025Mar 31, 2025$34.99M+91.5%
Q4 FY2024Dec 31, 2024$15.86M-64.6%
Q3 FY2024Sep 30, 2024$12.47M-61.2%
Q2 FY2024Jun 30, 2024$17.41M-15.6%
Q1 FY2024Mar 31, 2024$18.27M-14.7%
Q4 FY2023Dec 31, 2023$44.74M–
Q3 FY2023Sep 30, 2023$32.17M+787.9%
Q2 FY2023Jun 30, 2023$20.63M–
Q1 FY2023Mar 31, 2023$21.42M–
Q4 FY2022Dec 31, 2022-$4.40M–
Q3 FY2022Sep 30, 2022$3.62M–
Q2 FY2022Jun 30, 2022-$11.48M-4865.1%
Q1 FY2022Mar 31, 2022-$18.94M-191.6%
Q4 FY2021Dec 31, 2021-$12.19M–
Q3 FY2021Sep 30, 2021-$5.40M–
Q2 FY2021Jun 30, 2021$241.00K-98.8%
Q1 FY2021Mar 31, 2021$20.67M+1108.7%
Q4 FY2020Dec 31, 2020-$5.71M-218.9%
Q3 FY2020Sep 30, 2020-$1.61M-107.4%
Q2 FY2020Jun 30, 2020$20.88M+340.1%
Q1 FY2020Mar 31, 2020$1.71M-88.0%
Q4 FY2019Dec 31, 2019$4.80M-82.4%
Q3 FY2019Sep 30, 2019$21.79M+162.0%
Q2 FY2019Jun 30, 2019$4.74M-44.8%
Q1 FY2019Mar 31, 2019$14.29M-37.7%
Q4 FY2018Dec 31, 2018$27.23M+72.3%
Q3 FY2018Sep 30, 2018$8.32M-51.3%
Q2 FY2018Jun 30, 2018$8.59M+859200.0%
Q1 FY2018Mar 31, 2018$22.93M+251.2%
Q4 FY2017Dec 31, 2017$15.81M+30.8%
Q3 FY2017Sep 30, 2017$17.08M+1476.0%
Q2 FY2017Jun 30, 2017$1.00K–
Q1 FY2017Mar 31, 2017$6.53M–
Q4 FY2016Dec 31, 2016$12.08M–
Q3 FY2016Sep 30, 2016$1.08M–

More ANI Pharmaceuticals figures

See a number that looks wrong?